Clinical OMICS

SEP-OCT 2018

Healthcare magazine for research scientists, labs, pathologists, hospitals, cancer centers, physicians and biopharma companies providing news articles, expert interviews and videos about molecular diagnostics in precision medicine

Issue link: https://clinicalomics.epubxp.com/i/1023557

Contents of this Issue

Navigation

Page 19 of 51

18 Clinical OMICs September/October 2018 www.clinicalomics.com sequencing (WGS) metagenomic data from human stool specimens using the Illumina Nextera XT and Illumina TruSeq DNA PCR-free kits, and the KAPA Biosystems Hyper Prep PCR and PCR-free systems. "Our study highlights a critical need for consistency in protocols and data analysis procedures, especially when attempting to interpret human microbiome data for human health," concluded the research team, led by Marcus Jones, Ph.D., who at the time held positions with HLI and JCVI. He is now senior manager, R&D, planning, and strategy with Regeneron Pharmaceuticals. Jones did not respond to a Clinical OMICs query about the collaboration, and whether any other research came out of it. For much of its existence, HLI has been buffeted by turn- over among its top executives (see sidebar). Venter relin- quished his CEO position the first time in January 2017, and was succeeded by a GE executive, Cynthia Collins. When she resigned in December 2017, three other HLI executives joined her in leaving: COO Gary G. Altman, Ph.D., CMO Brad Perkins, M.D.; and the head of oncology and immuno- therapy, Kenneth J. Bloom, M.D. Venter then succeeded Collins as interim CEO, only to leave HLI May 24, saying in a tweet that he retired and "will be returning to the J. Craig Venter Institute to continue my work." HLI didn't appoint a successor until July 13, when it named its chief of radiogenomics David Karow, M.D., Ph.D., as interim CEO. (continued from previous page) Turmoil at the Top For most of its existence, Human Longevity Inc. (HLI) has been buffeted by executive comings and goings. Here's a list highlighting much of the turmoil at the top: Chief Executive Officer J. Craig Venter, Ph.D. March 2014–January 2017; interim CEO, December 2017–May 2018 Announced his retirement from HLI on May 24; HLI says Dr. Venter was terminated. Remains founder, chairman and CEO, J. Craig Venter Institute. Cynthia Collins January–December 2017 Previously at GE, where she was CEO/ general manager for GE Healthcare's Cell Therapy and Purification and Analysis Businesses, and earlier was CEO of GE's Clarient Diagnostics. Resigned from HLI in December 2017. Her LinkedIn page lists several short- term board appointments since then, and one current appointment: Since February, she has served on the board of the ARM Foundation for Cell and Gene Medicine. David Karow, M.D., Ph.D. Appointed July 13 as Interim CEO Joined HLI in June 2017 as chief of radiogenomics. Previously spent two decades in research, clinical practice and training positions at University of California San Diego, University of California Los Angeles and the University of Michigan, Ann Arbor. Chief Operating Officer Mark A. Winham Appointed August 2015 Previously COO, Millennium Health, and VP, Global Manufacturing, Life Technologies (since acquired by Thermo Fisher Scientific) Resigned from HLI February 2017; now chief scientific and operating officer, Wamberg Genomic Advisors. Gary G. Altman, Ph.D. Appointed May 2017 Previously President, U.S. Operations, Cavidi. Also served as managing director, G. Altman & Associates from April 2001 to January 2018. Resigned from HLI December 2017; now CEO of Provista Diagnostics. Nino Fanlo Appointed December 2017 Previously CFO of online lender Social Finance (SoFi). Resigned in spring 2018, months after The New York Times published allegations he sexually harassed women before joining the company while he was at SoFi. Fanlo has denied any wrongdoing. Scott Sorensen Appointed July 13 to interim COO position Joined HLI in March 2018 as CTO, a position he continues to hold. Previously CTO, Ancestry. Chief Medical Officer Brad Perkins, M.D. Appointed April 2014 Previously principal and founder, Longitude86W, an early–stage venture advisor and investor focused on health and well- being, healthcare, and sustainability. Resigned December 2017; now co-founder, director, and CEO, Sapiens Data Science. Adrian Weinbrecht / Getty Images

Articles in this issue

Links on this page

Archives of this issue

view archives of Clinical OMICS - SEP-OCT 2018